1.89%| Prev Close: | 47.33 |
|---|---|
| Open: | 47.60 |
| Bid: | 46.52 x 200 |
| Ask: | 47.08 x 300 |
| 1y Target Est: | 50.11 |
| Beta: | 0.39 |
| Next Earnings Date: | N/A |
| Day's Range: | 46.49 - 48.30 |
|---|---|
| 52wk Range: | 37.02 - 48.79 |
| Volume: | 42,629,592 |
| Avg Vol (3m): | 17,284,500 |
| Market Cap: | 141.05B |
| P/E (ttm): | 23.83 |
| EPS (ttm): | 1.96 |
| Div & Yield: | 1.72 (3.70%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Merck Announces First-Quarter 2013 Financial Resultsat noodls(Wed 1 May)
- Merck Announces New $15 Billion Share Repurchase Programat noodls(Wed 1 May)
- Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanomaat noodls(Wed 24 Apr)
- Merck Opens New Manufacturing Facility in Hangzhou, Chinaat noodls(Tue 16 Apr)
- Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Diseaseat noodls(Thu 14 Mar)
- Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization AgreementBusiness Wire(Wed 20 Feb)
- BioPharm Insight – Sirona in active discussions to out-license preclinical SGLT-2 antidiabetic candidate – CEOat noodls(Wed 9 Jan)
- Merck Increases Quarterly Dividendat noodls(Wed 28 Nov)
- PropThink: Endocyte - A Safe Bet for 2013ACN Newswire(Fri 9 Nov)
- Merck Announces Third-Quarter 2012 Financial Resultsat noodls(Fri 26 Oct)
- Theravance Narrows Y/Y LossZacks(Thu 14 Feb)
- Cardiome Selects QuintilesZacks(Wed 13 Feb)
- UPS Expands in Health Care MarketsZacks(Fri 8 Feb)
- Merck Beats, Issues OutlookZacks(Sat 2 Feb)
- Pipeline Progress at EndocyteZacks(Fri 1 Feb)
Press Releases
- Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization AgreementBusiness Wire(Wed 20 Feb)
- PropThink: Endocyte - A Safe Bet for 2013ACN Newswire(Fri 9 Nov)
- PropThink: MRK Earnings Upside; Top-Line Miss No Big Deal, Dividend Continues To SupportACN Newswire(Fri 26 Oct)